Table 1.

Summary of l-ASP pharmacology experiments

Cell lineMean EC50 (units/mL)95% Confidence intervalType
2221.611.21-2.12Endometrioid adenocarcinoma
A2240.360.33-0.39Papillary serous adenocarcinoma
A27800.220.20-0.24Papillary serous adenocarcinoma
A3640.250.22-0.29Papillary serous adenocarcinoma
A5470.190.11-0.34Papillary serous adenocarcinoma
AD100.240.22-0.27Papillary serous adenocarcinoma
CaOV35.043.77-6.74Papillary serous adenocarcinoma
IGROV1 (NCI)1.100.45-2.67Adenocarcinoma
OVCAR-3 (NCI)1.190.94-1.50Adenocarcinoma
OVCAR-30.860.56-1.32Papillary serous adenocarcinoma
OVCAR-4 (NCI)5.484.27-7.02Adenocarcinoma
OVCAR4200.300.21-0.42Adenocarcinoma
OVCAR4290.400.28-0.58Serous cystadenocarcinoma
OVCAR4320.290.23-0.36Adenocarcinoma
OVCAR-8 (NCI)0.490.44-0.53Adenocarcinoma
OVCAR-8/ADR (NCI)0.200.17-0.23Adenocarcinoma
SKOV3 (NCI)0.180.10-0.31Papillary serous adenocarcinoma
SKOV30.290.25-0.33Papillary serous adenocarcinoma
UCI1017.711-82Papillary serous adenocarcinoma